Wire · opportunities
Madrigal's Rezdiffra storms past blockbuster milestone as CEO hails 'accelerating' MASH market
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 November 2026 · Fusion42 review
Madrigal Pharmaceuticals' Rezdiffra, the first FDA-approved therapy for metabolic dysfunction-associated steatohepatitis (MASH), surpassed $1 billion in annual sales, driven by rapid market growth and expanding patient treatment. The company is advancing pivotal trials to convert accelerated approval into full approval and to address the high-unmet-need cirrhosis and portal hypertension markets.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a growing opportunity as Madrigal sets a new bar in liver disease treatment with Rezdiffra’s blockbuster sales and aggressive trial plans. Expect market entry windows to widen and standards to rise, especially around advanced cirrhosis and portal hypertension therapies.
◆ Coverage
1 source · 3 Nov 2026
◆ Related on Wire
◆ Topics